Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
Authors:
Open Access
- 1 September 2021
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 2591-2604
Abstract
Background: Available data on the relationship between COPD symptoms, disease outcomes, and mortality are currently limited. This study investigated the clinical characteristics, outcomes, healthcare utilization, and prescribing practices across GOLD 2017 groups (A, B, C, and D) in a large-scale, population-based cohort of COPD patients managed in an English primary care setting. Patients and Methods: This retrospective analysis included patients aged ≥ 35 years, with a confirmed diagnosis of COPD and ≥ 1 record of pulmonary function testing in their medical history. Medical Research Council dyspnea score and exacerbation history were used to define patients’ GOLD 2017 classification. Patients were identified using the UK Clinical Practice Research Database and were followed for 12 months. Results: Eligible COPD patients’ (N=42,331; mean [SD] age, 69.5 [10.7] years; 54% males), GOLD 2017 categorizations were: Group A: 49.1%, Group B: 30.5%, Group C: 8.2%, Group D: 12.1%. Overall, 37.7% of patients experienced ≥ 1 moderate COPD exacerbation. The rate of moderate exacerbations per person per year (PPPY) was highest in GOLD group D (0.72), followed by C (0.53), B (0.22), and A (0.15), while the rate of exacerbations leading to hospitalization PPPY was much higher in D (0.27) than in B (0.10), C (0.08), or A (0.03). Overall, 56.4% of patients visited their general practitioner ≥ 5 times in the 12 months of follow-up. Time-to-event analysis suggested that breathlessness contributed to exacerbation severity and frequency. One-year mortality was highest in GOLD groups D and B. The most frequent prescribed maintenance therapies were inhaled corticosteroids with long-acting β2-agonists, multiple-inhaler triple therapy, or long-acting muscarinic antagonist, irrespective of GOLD classification. Conclusion: The burden of COPD remains substantial in England. Stratification of this large primary care population according to GOLD criteria predicted the risk of COPD exacerbations. Understanding populations of patients with COPD may enable the optimization of patient care.Keywords
This publication has 27 references indexed in Scilit:
- Hospitalized Exacerbations of COPDChest, 2015
- The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort studyBMJ Open, 2014
- Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD)BMJ Open, 2014
- Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease Guidelines for Predicting Mortality and HospitalizationAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohortEuropean Respiratory Journal, 2013
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Prediction of the Clinical Course of Chronic Obstructive Pulmonary Disease, Using the New GOLD Classification: A Study of the General PopulationAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Exacerbation frequency and course of COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2012
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Epidemiology and costs of chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 2006